The subsequent GSDC2 screen assayed 297 compounds against 969 cancer lines, using a different ATP-based proliferation assay (CellTiter-Glo), and no association between CDKN2A loss/mutation and palbocicilib sensitivity was observed4. This evidence concerns the gene CDKN2A and cancer.